
Lupin inks $50 million licensing deal with Zentiva for global biosimilar rollout
Pharma major Lupin has entered into a strategic licensing and supply agreement with Czech-based Zentiva to commercialize its biosimilar version of Certolizumab Pegol across multiple global markets. Under this agreement, Zentiva will be responsible for …